



WEDNESDAY, 15th MAY 2019 COMMENCING 10:30 AM
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/0519

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Limited Submission (PAS)** 2/AWMSG/0519
Fingolimod (Gilenya[®]) a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of paediatric patients aged 10-17 years of age: for patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI
Appendices

The meeting will now open to the public for the committee decisions

6. **Chairman's report (verbal update)**
7. **Appraisal 2: Full Submission** 3/AWMSG/0519
Doxylamine succinate/pyridoxine hydrochloride (Xonvea[®]) for the treatment of nausea and vomiting of pregnancy in those patients who do not respond to conservative management
Appendices
8. **All Wales COPD Management and Prescribing Guide** 4/AWMSG/0519
9. **Antimicrobial Drug Chart** 5/AWMSG/0519
10. **National Prescribing Indicators 2018-19 Analysis of Prescribing Data to December 2018** 6/AWMSG/0519
11. **Feedback from AWPAG meeting held on 20th March 2019** 7/AWMSG/0519

Date of next meeting – Wednesday, 19th June 2019 in Cardiff